Skip to content
BOLUS

Signal from the log

Encoded Therapeutics

275 M$ · Series D and later · United States · Biotech

Société de South San Francisco qui développe des médicaments génétiques de précision en neurologie. ETX101 est une thérapie génique AAV9 en dose unique contre le syndrome de Dravet lié à SCN1A, une épilepsie génétique du nourrisson. L'argent finance l'étude pivot chez le nourrisson et une extension jusqu'à dix-huit ans.

Verified

Announced on , logged by the watch of 9 September 2026.

Operation
Funding round
Announced amount
275 M$
Stage
Series D and later
Country
United States
Sector
Biotech

What the log says

Editorial note, in French

Communiqué ouvert, montant relu et fonds nommés.

The investors

Led by GV , with ARCH Venture Partners , Braidwell , Farallon Capital Management , Illumina Ventures , Invus , Janus Henderson Investors , Matrix Capital Management , Nolan Capital , RTW Investments , SoftBank Vision Fund 2 , Venrock

Provenance
Source businesswire,endpoints,pulse2
Logged on 9 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.

One address, nothing else.

One letter a week, on Fridays: the week's funding rounds, the funds named, the amounts double checked. The list is never sold, one click to unsubscribe. The letter is written in French.

Email confirmation before any subscription. The list is never sold. What Bolus knows about you is written on the privacy page (in French).